Answers are grounded in this paper and cite their sources.
Palbociclib causes reversible bone marrow suppression, clearly differentiating it from apoptotic cell death caused by cytotoxic chemotherapeutic agents. This study also distinguished the cell-cycle arresting action of palbociclib on normal bone marrow cells from the senescent effects observed in breast cancer cells. These results shed light on the mechanism and support risk management of palbociclib-induced bone marrow toxicity in the clinic.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: